Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
QNRX | US
-0.03
-0.52%
Healthcare
Biotechnology
30/06/2024
24/04/2026
5.70
5.60
5.74
5.32
Quoin Pharmaceuticals Ltd. a clinical stage specialty pharmaceutical company focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003 a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn Virginia.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
52.7%1 month
128.0%3 months
100.5%6 months
140.6%-
-
0.45
0.43
0.23
-0.42
-
-
-8.84M
22.69M
22.69M
-
-
-
-
-100.03
0.01
0.38
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.66
Range1M
5.51
Range3M
5.51
Rel. volume
0.43
Price X volume
576.57K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CELU | CELU | Biotechnology | 1.11 | 24.40M | -0.89% | n/a | 127.38% |
| Edesa Biotech Inc | EDSA | Biotechnology | 7.26 | 23.58M | 7.08% | n/a | 1.35% |
| Evaxion Biotech A/S | EVAX | Biotechnology | 4.03 | 22.48M | -5.18% | n/a | 837.11% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.8566 | 20.55M | -4.82% | n/a | 0.00% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 6.4 | 20.46M | 4.40% | n/a | 14.63% |
| Enlivex Therapeutics Ltd | ENLV | Biotechnology | 0.8885 | 19.02M | -2.01% | n/a | 2.92% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.88 | 18.75M | -2.59% | n/a | 3.49% |
| PLUR | PLUR | Biotechnology | 3.345 | 18.30M | -2.76% | n/a | 30845.83% |
| DOMH | DOMH | Biotechnology | 2.89 | 18.14M | 0.00% | n/a | 7.66% |
| DarT Bioscience Inc | DARE | Biotechnology | 2.11 | 18.03M | -0.47% | 0.12 | 218.34% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.42 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.45 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 100.47 | 72.80 | Riskier |
| Debt to Equity | 0.43 | -1.23 | Expensive |
| Debt to Assets | 0.23 | 0.25 | Par |
| Market Cap | 22.69M | 3.66B | Emerging |